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Abstract: Systemic sclerosis (SSc; scleroderma) is characterized by life-threatening progressive
multiorgan fibrosis orchestrated by profibrotic myofibroblasts originating from different sources.
Because recent data demonstrated that the majority of myofibroblasts in a murine scleroderma
model arise from adipocytic progenitors through the adipocyte-myofibroblast transition process,
we sought to determine whether the SSc microenvironment may affect the differentiation potential
of adipose-derived stem cells (ADSC). Normal human ADSC from three donors were treated with
serum from SSc patients (n = 6), serum from healthy individuals (n = 6), or recombinant human
transforming growth factor-β1 (TGFβ1) as positive control of myofibroblastic phenotype induction.
ADSC were subjected to in vitro adipogenic differentiation for up to 21 days in the presence of
different stimuli followed by lipid content quantification. In selected experiments, adipocytic and
mesenchymal/myofibroblast marker gene and protein expression levels were assessed by Real-Time
PCR, immunoblotting and immunofluorescence after administration of different stimuli for 72 and
96 h, respectively. Cell contractile phenotype was assayed by collagen gel contraction assay. Likewise
stimulation with TGFβ1, SSc serum was able to significantly inhibit the adipocyte differentiation
of ADSC as testified by a strong decrease in red-colored lipid droplets after 21 days of adipogenic
induction. Treatment of ADSC either with SSc serum or TGFβ1 resulted in the acquisition of a
myofibroblast-like phenotype characterized by a reduced expression of the adipocytic markers
perilipin and adiponectin, a significant upregulation of the mesenchymal/myofibroblast markers
α-SMA+ stress fibers, S100A4 and type I collagen, and an ability to effectively contract collagen
gels. In SSc, the pathologic environment may favor the differentiation of ADSC into profibrotic
and contractile myofibroblast-like cells. These findings strengthen the notion that the generation of
myofibroblasts from ADSC may be relevant in SSc pathophysiology potentially representing a new
target for the prevention/treatment of multiorgan fibrosis.
Keywords: systemic sclerosis; scleroderma; fibrosis; adipose-derived stem cells; myofibroblasts;
myofibroblastic differentiation
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1. Introduction
Systemic sclerosis (SSc; scleroderma) is a connective tissue disease characterized by dysregulation
of innate and adaptive immunity, severe alterations in the microvasculature and progressive
development of fibrotic lesions in the skin and internal organs [1–3]. The key cellular players responsible
for SSc-related fibrosis are activated myofibroblasts, a population of mesenchymal cells that exhibit both
the extracellular matrix (ECM)-synthesizing features of fibroblasts and the cytoskeletal characteristics
of contractile smooth muscle cells [4–6]. Profibrotic myofibroblasts display an increased production of
fibrillar type I and type III collagens, as well as the expression and incorporation into stress fibers of
α-smooth muscle actin (α-SMA) and a shortage of ECM-degrading enzymes [4–6]. In the skin of SSc
patients, the presence of myofibroblasts correlates with a number of parameters of fibrosis such as
tightness, hardness and stiffness, supporting a role for these profibrotic cells in different disease clinical
signs [4]. Besides the skin, in SSc myofibroblasts can be observed in any organ affected by fibrosis
including the lungs, gastrointestinal tract, kidneys, and myocardium [7–10].
Although tissue accumulation of myofibroblasts and the persistence of their elevated biosynthetic
functions are regarded as crucial determinants of the extent and rate of progression of the SSc-related
fibrotic process, the initial pathogenic events leading to the appearance of these cells remain a
matter of debate [1,4,5]. Indeed, increasing evidence suggests that myofibroblasts may arise from
different sources including expansion and activation of resident tissue fibroblasts and perivascular
pericytes, recruitment of bone marrow-derived circulating precursors, and transdifferentiation of
epithelial and endothelial cells [6,11–13]. Interestingly, recent studies have also revealed that, in the
course of fibrosis, adipocyte progenitors (i.e., preadipocytes) may transdifferentiate into contractile
myofibroblasts through a process termed adipocyte-myofibroblast transition [14–16]. In fact, by
using a transgenic lineage tracing approach in experimental murine scleroderma, it was possible to
demonstrate that the loss of intradermal adipose tissue precedes the onset of dermal fibrosis and
is accompanied by early downregulation of adipocyte-associated genes followed by an acquisition
of myofibroblast-associated genes [14]. Strikingly, development of skin fibrosis in SSc patients is
accompanied by loss of dermal white adipose tissue [15], a phenotype well recapitulated in different
animal models of skin fibrosis [17–23]. Moreover, adipose tissue replacement with fibrotic tissue has
been observed in other pathologies such as liver fibrosis and cancers [24–28]. Of note, it has been
reported that stimulation of either undifferentiated human adipose-derived stem cells (ADSC) or
ADSC committed to preadipocytes with profibrotic transforming growth factor-β (TGFβ) is able to
induce the loss of adipocytic markers and the reciprocal acquisition of mesenchymal/myofibroblast
markers [14,29]. In vitro experiments on different adipocyte-generating cultures further showed that
myofibroblast differentiation may be driven not only by TGFβ [14], but also by other pathways such as
FIZZ1 and Wnt signaling [23,30,31].
Several studies have also suggested that SSc patients may benefit from fat tissue grafting
thanks to its biocompatibility, property of filling and high content of multipotent mesenchymal-like
stem/progenitor cells, such as ADSC, that reside in the so-called stromal vascular fraction (SVF) and may
display regenerative, anti-inflammatory, immunosuppressive, and proangiogenic activities [32–37]. In
a model of scleroderma-like skin sclerosis in nude mice, subcutaneous injections of SVF significantly
decreased dermal fibrosis and increased local vascularization [38]. Autologous fat implantation in
hands of patients with SSc led to significant pain relief and decrease in the number, duration, and
severity of Raynaud’s phenomenon attacks [39]. An improvement of digital ulcers was also reported
in a small group of SSc patients after autologous adipose-derived SVF injection [40]. Furthermore, a
significant reduction in skin tightening was observed in SSc patients subjected to transplantation of
ADSC in hyaluronic acid solution [41]. Encouraging results on the safety, tolerability and potential
efficacy of autologous adipose-derived SVF injection to treat hand disability in SSc patients have
also emerged from a small clinical trial and subsequent follow-up analyses [42–44]. Although the
aforementioned reports suggest that autologous SVF might be a valuable source of therapeutic
stem/progenitor cells, the exact role of the ADSC contained within the SVF could not be established
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leaving undetermined whether these cells may be optimally effective in SSc patients. Indeed, a recent
study reported that SSc SVF-derived ADSC, though retaining high multipotency, fail to differentiate
into fully mature adipocytes, osteocytes and chondrocytes [45]. A differential molecular signature
reflecting deregulation of angiogenesis, endothelial activation and fibrosis was also detected in SSc
SVF when compared with healthy SVF [46]. As previously reported for SSc bone marrow-derived
mesenchymal stem/stromal cells [47], in vitro-expanded SSc ADSC at early passages have been found
to display a profibrotic and anti-adipogenic phenotype [29]. Collectively, these data suggest that the
specific pathologic tissue environment may be crucial in affecting the differentiation potential and
behavior of ADSC.
On this background, the objective of our in vitro study was to investigate for the first time how
and in which extent the SSc microenvironment may influence the fate of human ADSC. In particular, we
aimed at comprehensively exploring whether treatment with sera from SSc patients may either affect
the differentiation of normal human ADSC into mature adipocytes or promote their differentiation
toward profibrotic myofibroblasts.
2. Materials and Methods
2.1. Patients and Serum Samples
Serum samples were obtained from 6 patients with early diffuse cutaneous SSc (dcSSc;
disease duration <2 years from first non-Raynaud symptom) fulfilling the American College of
Rheumatology/European League Against Rheumatism 2013 classification criteria [48] and from 6 age-
and sex-matched healthy volunteers. SSc patients were not on immunosuppressors, corticosteroids or
other disease-modifying drugs. Before blood sampling, patients were washed out for 10 days from
oral vasodilating drugs and for 2 months from intravenous prostanoids. Fresh venous blood samples
were drawn, left to clot for 30 min before centrifugation at 1500× g for 15 min, and serum was collected
and stored in aliquots at −80◦C until used. The study was conducted according to the principles
of the Declaration of Helsinki and approved by the local institutional review board at the Azienda
Ospedaliero-Universitaria Careggi (AOUC), Florence, Italy (AOUC 69/13). All individuals provided
written informed consent.
2.2. Culture of Human ADSC
Three lines of normal human ADSC were purchased from Lonza (catalog no. PT-5006; Lonza,
Basel, Switzerland) and were routinely maintained in ADSC complete medium (ADSC human Adipose
Derived Stem Cell Growth BulletKitTM Medium; catalog no. PT-4505; Lonza) at 37 ◦C in a 5%
CO2 incubator.
2.3. In Vitro Differentiation of Human ADSC into Mature Adipocytes
ADSC were seeded into 6-well culture plates at a density of 2 × 105 cells/well in ADSC complete
medium and cultured for 6 days. Once at confluence, cells were treated with fresh adipogenic
induction medium (ADSC complete medium supplemented with 1 µM dexamethasone, 0.5 mM
3-isobutyl-1-methylxanthine, 60 µM indomethacin, and 10 µg/mL recombinant human insulin) for
72 h and, subsequently, with fresh adipogenic maintenance medium (ADSC complete medium with
10 µg/mL recombinant human insulin) for 24 h in the presence of the following stimuli: recombinant
human TGFβ1 (10 ng/mL; PeproTech, Rocky Hill, NJ, USA) or 10% serum from patients with early
dcSSc (n = 6) and healthy individuals (n = 6). Each serum sample was tested individually. This protocol
was repeated up to 3 weeks. ADSC were characterized by Oil red O staining at 7, 14, and 21 days
following adipogenic induction medium/maintenance medium plus stimuli addition.
2.4. Oil Red O Staining
Oil red O powder was obtained from Sigma-Aldrich (catalog no. O0625; Sigma-Aldrich, St. Louis,
MO, USA). A stock solution was prepared by dissolving 50 mg of Oil red O powder in 50 mL 2-propanol
and diluted with distilled water (2:3 ratio) to obtain a working solution. ADSC were fixed with 4%
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formaldehyde in phosphate buffered saline (PBS) for 20 min at room temperature. Formaldehyde
was removed and Oil red O working solution was added to the 6-well plates for 10 min at room
temperature. After washing with distilled water phase-contrast images were captured using a Leica
inverted microscope (Leica Microsystems, Mannheim, Germany) equipped with a digital camera. Oil
red O staining was quantified after 21 days by adding 100% 2-propanol (2.5 mL per well) to elute
the dye followed by plate incubation for 10 min at room temperature on an orbital shaker. For each
experimental point, 400 µL of eluate were transferred into two wells of a 96-well microtiter plate
(200 µL per well). Absorption was measured in duplicate at 510 nm in a Promega GloMax Multi
Detection Microplate Reader (Promega Corporation, Madison, WI, USA).
2.5. Stimulation of Human ADSC to Assess Myofibroblastic Differentiation
In selected experiments, ADSC were grown to 70% confluence, washed three times with serum-free
medium and cultured in ADSC basal medium (catalog no. PT-3273, Lonza) supplemented with 2% fetal
bovine serum for 24 h. Medium was removed and cells were then incubated in ADSC basal medium
supplemented with 2% fetal bovine serum and recombinant human TGFβ1 (10 ng/mL; PeproTech)
or 10% serum from patients with early dcSSc (n = 6) and healthy individuals (n = 6) for 72 and 96 h
for subsequent analyses of mRNA and protein expression levels of relevant markers, respectively.
Each serum sample was tested individually. The medium was changed, and additives replenished,
every day.
2.6. RNA Isolation and Quantitative Real-Time PCR
Seventy-two h after stimulation, ADSC were harvested and total RNA was isolated using the
RNeasy Micro Kit (Qiagen, Milan, Italy). First strand cDNA was synthesized using the QuantiTect
Reverse Transcription kit (Qiagen). For mRNA quantification, SYBR Green Real-Time PCR was
performed using the StepOnePlus Real-Time PCR System (Applied Biosystems, Milan, Italy) with
melting curve analysis. Predesigned oligonucleotide primer pairs were obtained from Qiagen
(QuantiTect Primer Assay). The assay IDs were: Hs_PLIN1_1_SG (perilipin-1; catalog no. QT00017486),
Hs_ADIPOQ_va.1_SG (adiponectin; catalog no. QT02409862), Hs_ACTA2_1_SG (α-SMA; catalog
no. QT00088102), Hs_S100A4_1_SG (S100 calcium binding protein A4; catalog no. QT00014259),
Hs_COL1A1_1_SG (collagen, type I, alpha 1; catalog no. QT00037793), Hs_COL1A2_1_SG (collagen,
type I, alpha 2; catalog no. QT00072058), and Hs_RRN18S_1_SG (18S ribosomal RNA; catalog no.
QT00199367). 18S ribosomal RNA was measured as an endogenous control to normalize for the
amounts of loaded cDNA. Differences were calculated with the threshold cycle (Ct) and comparative
Ct method for relative quantification. All measurements were performed in triplicate.
2.7. Fluorescence Immunocytochemistry
ADSC were seeded onto glass coverslips and stimulated as already described for 96 h. Cells
were then fixed with 3.7% buffered paraformaldehyde and permeabilized with 0.1% Triton X-100 in
PBS. Slides were washed with PBS and blocked with 1% bovine serum albumin in PBS for 1 h at
room temperature. Double immunofluorescence staining was performed overnight at 4 ◦C by mixing
mouse and rabbit primary antibodies. The following primary antibodies were used: Rabbit polyclonal
anti-perilipin-1 (1:80 dilution; catalog no. ab3526; Abcam, Cambridge, UK), mouse monoclonal
anti-α-SMA (1:50 dilution; catalog no. ab7817; Abcam), mouse monoclonal anti-type I collagen
(1:100 dilution; catalog no. ab90395; Abcam), mouse monoclonal anti-adiponectin (1:100 dilution;
catalog no. ab22554; Abcam) and rabbit monoclonal anti-S100A4/fibroblast-specific protein-1 (1:100
dilution; catalog no. ab124805; Abcam). Irrelevant isotype-matched and concentration-matched
mouse and rabbit IgG (Sigma-Aldrich) were used as negative controls. The day after, cells were
incubated for 45 min at room temperature in the dark with Alexa Fluor-488-conjugated or Rhodamine
Red-X-conjugated secondary antibodies at 1:200 dilution (Invitrogen, Carlsbad, CA, USA). Nuclei were
counterstained with 4′, 6-diamidino-2-phenylindole (DAPI). Immunostained cells were examined with
a Leica DM4000 B microscope (Leica Microsystems) and fluorescence images were captured with a
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Leica DFC310 FX 1.4-megapixel digital color camera equipped with the Leica software application
suite LAS V3.8 (Leica Microsystems).
2.8. Immunoblotting
Whole cell protein lysates from ADSC were collected 96 h after stimulation and subjected to
immunoblot analysis as described elsewhere [6]. The following primary antibodies from Abcam were
used: anti-perilipin-1 (1:500 dilution; catalog no. ab3526), anti-adiponectin (1:1000 dilution; catalog
no. ab22554), anti-α-SMA (1:500 dilution; catalog no. ab7817), anti-type I collagen (1:500 dilution;
catalog no. ab90395), and anti-S100A4 (1:1000 dilution; catalog no. ab124805). Anti-α-tubulin antibody
(1:1000 dilution; catalog no. #2144; Cell Signaling Technology, Danvers, MA, USA) was used for
normalization. Immunodetection was performed using the Western Breeze Chromogenic Western Blot
Immunodetection Kit (Invitrogen). Band intensities were quantified with the free-share ImageJ software
64-bit Java 1.8.0_112 Windows version (NIH, Bethesda, MD, USA; online at http://rsbweb.nih.gov/ij)
and normalized with the respective α-tubulin values.
2.9. Collagen Gel Contraction Assay
Collagen gel contraction assay was performed using the CytoSelectTM 24-Well Cell Contraction
Assay Kit (Floating Matrix Model; catalog no. CBA-5020; Cell Biolabs, San Diego, CA, USA) according
to the manufacturer’s instructions. ADSC were cultured in basal medium supplemented with 2% fetal
bovine serum for 24 h and then stimulated with recombinant human TGFβ1 (10 ng/mL; PeproTech)
or 10% serum from early dcSSc patients (n = 6) and healthy individuals (n = 6) for 96 h before the
assay. After treatment, ADSC were harvested, pelleted and resuspended in serum-free medium at
3 × 106 cells/mL. For each experimental point, 100 µL of the cell suspension was mixed with 400 µL of
cold neutralized collagen gel solution and subsequently added to one well of the adhesion resistant
matrix-coated 24-well cell contraction plate. Gels were allowed to solidify for 1 h at 37◦C and 5% CO2.
After polymerization, 1 mL of basal medium or medium containing different stimuli (i.e., recombinant
human TGFβ1, early dcSSc sera and healthy sera) was added to the top of each collagen gel lattice.
Gels without cells were included as negative controls. Each experimental point was performed in
triplicate. After 24 h, the culture dish was scanned and the area of each collagen gel was measured by
ImageJ software 64-bit Java 1.8.0_112 Windows version (NIH).
2.10. Determination of TGFβ1 Serum Levels
Levels of TGFβ1 in serum samples were measured by commercial quantitative colorimetric
sandwich enzyme-linked immunosorbent assay (ELISA) according to the manufacturer’s
recommendation (eBioscience, San Diego, CA, USA). The detection limit of the assay according
to the manufacturer was 8 pg/mL and the standard curve covered a concentration range from 8 to
1000 pg/mL. Concentrations were calculated using a standard curve generated with specific standards
provided by the manufacturer. Each sample was tested in triplicate.
2.11. Statistical Analysis
Statistical analyses were performed using the Statistical Package for Social Sciences software for
Windows, V.25.0 (SPSS, Chicago, IL, USA). Data are reported as the mean ± SD or SEM. Student’s
t-test was used for statistical evaluation of the differences between two independent groups. Values of
p < 0.05 according to a two-tailed distribution were considered statistically significant.
3. Results
3.1. Treatment with SSc Serum Significantly Inhibits the Adipogenic Differentiation Process of Normal
Human ADSC
Oil red O staining was employed to monitor the accumulation of intracellular lipids at 7, 14,
and 21 days of ADSC culture using a protocol directing differentiation into the mature adipocyte
phenotype in the presence of different stimuli. At all three experimental time points, under the
microscope, normal human ADSC from three donors challenged with recombinant human TGFβ1 and
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serum from patients with SSc showed decreased red-colored lipid droplets compared to both basal and
healthy serum-treated ADSC (Figure 1A). Quantitative analysis of intracellular lipid accumulation
revealed that after 21 days of culture in adipogenic differentiation medium in the presence of SSc
sera, the lipid content was strongly reduced compared with either cells in basal conditions or cells
cultured in the presence of healthy sera (p < 0.001 for both comparisons) (Figure 1B). Moreover, the
lipid content of cells treated with SSc sera was comparable to that of cells challenged with recombinant
human TGFβ1 (Figure 1B). Levels of TGFβ1 measured by ELISA were significantly higher in SSc serum
samples (mean ± SD values, 86.55 ± 23.12 pg/mL) than in healthy control serum samples (mean ± SD
values, 31.24 ± 17.64 pg/mL; p < 0.001).
Figure 1. Treatment with serum from patients with systemic sclerosis (SSc) significantly reduces the lipid
content in normal human adipose-derived stem cells (ADSC) cultured in adipogenic differentiation
medium. (A) Confluent ADSC were treated with fresh adipogenic induction medium for 72 h
and, subsequently, with fresh adipogenic maintenance medium together with different stimuli (i.e.,
recombinant human transforming growth factor-β1 (TGFβ1; 10 ng/mL), 10% serum from healthy
individuals (n = 6) or 10% serum from patients with early diffuse cutaneous SSc (n = 6)) for 24 h. This
protocol was repeated up to 3 weeks. Cells were subjected to Oil red O staining at 7, 14 and 21 days
following adipogenic induction medium/maintenance medium plus stimuli addition. Representative
images of Oil red O staining for each experimental point are shown. (B) The relative lipid content
values at 21 days are expressed as mean ± SEM of three independent experiments performed with three
ADSC lines. Basal ADSC lipid content was set to 1; the other results are expressed as x-fold change
over basal ADSC lipid content. Student’s t-test was used for statistical analysis. * p < 0.001 vs. basal
and healthy serum.
J. Clin. Med. 2019, 8, 1256 7 of 15
3.2. Treatment with SSc Serum Induces a Myofibroblast-Like Profibrotic and Contractile Phenotype in Normal
Human ADSC
Previous studies suggested that ADSC and adipocyte progenitors/preadipocytes can potentially
contribute to myofibroblast accumulation in the fibrotic skin of SSc patients [14–16,29]. Nevertheless,
whether the SSc microenvironment may influence the fate of normal human ADSC has never been
investigated. To address this issue, normal human ADSC were challenged with sera from patients with
SSc and healthy individuals and subsequently assayed for changes in gene and protein expression of
adipocytic and mesenchymal/myofibroblast markers. According to the literature [14,29], stimulation
with recombinant human TGFβ1 was performed in parallel as a positive control of myofibroblastic
phenotype induction.
After 72-h stimulation of ADSC with SSc sera, the gene expression levels of the adipocytic
markers PLIN1 (perilipin-1) and ADIPOQ (adiponectin) assessed by quantitative Real-Time PCR were
significantly decreased compared with either cells in basal conditions or cells treated with healthy sera
(p < 0.001 for both comparisons) (Figure 2). In parallel, we detected a significant upregulation of genes
encoding mesenchymal/myofibroblast markers, including ACTA2 (α-SMA), S100A4 (fibroblast-specific
protein-1), COL1A1 and COL1A2 (α1 and α2 chains of type I collagen) in ADSC challenged with SSc
sera (p < 0.001 vs. basal and healthy serum-treated ADSC for all genes) (Figure 2). As expected,
treatment of ADSC with recombinant human TGFβ1 significantly downregulated both PLIN1 and
ADIPOQ and upregulated ACTA2, S100A4, COL1A1, and COL1A2 gene expression levels (Figure 2).
These differences were maintained at the protein level as assessed by immunofluorescence and
immunoblotting analyses of adipocytic and mesenchymal/myofibroblast markers in cells stimulated
with sera for 96 h (Figure 3A,B).
As displayed in Figure 3A, ADSC were confirmed to be immunopositive for perilipin and
adiponectin, although the immunostaining for these adipocytic markers was markedly decreased
in cells challenged with SSc sera respect to those at basal conditions or stimulated with healthy
sera. Moreover, immunofluorescence staining revealed a strong increase in α-SMA+ stress fibers
and immunopositivity for type I collagen and S100A4 mesenchymal/myofibroblast markers in SSc
serum-treated ADSC compared with both basal and healthy serum-treated ADSC (Figure 3A). The
immunophenotypic changes of cells stimulated with SSc sera were comparable to those of cells treated
with recombinant human TGFβ1 (Figure 3A).
Immunoblotting analyses confirmed either significantly lower protein levels of perilipin and
adiponectin or significantly higher protein levels of α-SMA, type I collagen and S100A4 in both ADSC
challenged with SSc sera and those treated with recombinant human TGFβ1 compared with basal
ADSC and ADSC treated with healthy sera (p < 0.001 for all markers) (Figure 3B).
The ability of SSc serum to induce a myofibroblastic differentiation of ADSC was confirmed
functionally by the collagen gel contraction assay. In fact, similarly to stimulation with recombinant
human TGFβ1, 96-h treatment with SSc sera was able to fully promote the acquisition of a
myofibroblast-like contractile phenotype, as demonstrated by a significant reduction in collagen
gel area (p < 0.001 vs. basal and healthy serum-treated ADSC) (Figure 4A,B).
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Figure 2. Treatment with systemic sclerosis (SSc) serum induces changes in gene expression levels
of adipocytic and mesenchymal/myofibroblast markers in normal human adipose-derived stem cells
(ADSC). ADSC were treated for 72 h with recombinant human transforming growth factor-β1 (TGFβ1;
10 ng/mL), 10% serum from healthy individuals (n = 6) or 10% serum from patients with early diffuse
cutaneous SSc (n = 6) and subsequently assayed for mRNA expression levels of PLIN1 (perilipin),
ADIPOQ (adiponectin), ACTA2 (α-smooth muscle actin), S100A4 (fibroblast-specific protein-1), COL1A1
and COL1A2 (α1 and α2 chains of type I collagen, respectively) by quantitative Real-Time PCR. 18S
ribosomal RNA was measured as an endogenous control for normalization. For each gene, the mRNA
expression in basal cells was set to 1; the other results are expressed as x-fold increase/decrease over
basal response. Bars represent the mean ± SEM. Results are representative of three independent
experiments performed with three ADSC lines. Statistical analysis was carried out with Student’s t-test.
* p < 0.001 vs. basal and healthy serum.
J. Clin. Med. 2019, 8, 1256 9 of 15
Figure 3. Treatment with serum from patients with systemic sclerosis (SSc) induces changes in
protein expression levels of adipocytic and mesenchymal/myofibroblast markers in normal human
adipose-derived stem cells (ADSC). ADSC were treated for 96 h with recombinant human transforming
growth factor-β1 (TGFβ1; 10 ng/mL), 10% serum from healthy individuals (n = 6) or 10% serum from
patients with early diffuse cutaneous SSc (n = 6) and subsequently assayed for protein expression levels
of adipocytic markers (perilipin and adiponectin) and mesenchymal/myofibroblast markers (α-smooth
muscle actin (α-SMA), type I collagen and S100A4/fibroblast-specific protein-1). (A) Representative
fluorescence microphotographs showing ADSC double immunostained for perilipin (red) and α-SMA
(green), perilipin (red) and type I collagen (green), and adiponectin (green) and S100A4 (red)
are shown in the upper, middle and lower panels, respectively. Nuclei are counterstained with
4′,6-diamidino-2-phenylindole (DAPI; blue). Treatment of ADSC either with SSc sera or TGFβ1,
but not with healthy sera, induces downregulation of perilipin and adiponectin in parallel with an
increase in α-SMA+ stress fibers, type I collagen and S100A4. Scale bar = 50 µm. (B) Representative
immunoblots are shown. α-tubulin was measured as a loading control. Results are representative of
three independent experiments performed with three ADSC lines. The densitometric analysis of the
bands normalized to α-tubulin is reported in the histograms. Data are mean ± SEM of optical density.
Student’s t-test was used for statistical analysis. * p < 0.001 vs. basal and healthy serum for each protein.
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Figure 4. Normal human adipose-derived stem cells (ADSC) treated with serum from systemic sclerosis
(SSc) patients acquire the ability to effectively contract collagen gel. (A) Representative images of
collagen gel contraction assay with ADSC at basal conditions and after treatment with recombinant
human transforming growth factor-β1 (TGFβ1; 10 ng/mL), 10% serum from healthy individuals (n = 6)
or 10% serum from patients with early diffuse cutaneous SSc (n = 6) for 96 h. Results are representative of
three independent experiments performed with three ADSC lines. (B) Gel area expressed as percentage
of that observed in basal ADSC. Data are mean± SEM. Statistical analysis was carried out with Student’s
t-test. * p < 0.001 vs. basal and healthy serum.
4. Discussion
Our data demonstrate for the first time that normal human ADSC can acquire an anti-adipogenic
and profibrotic phenotype in response to treatment with serum of SSc patients, suggesting that a
preferential differentiation of these stem cells into myofibroblasts may take place in SSc and contribute
to the reduction in dermal white adipose tissue and its replacement by fibrotic tissue. In fact, a
prolonged challenge with SSc sera was able to significantly inhibit the adipocyte differentiation process
of ADSC as testified by a strong decrease in red-colored lipid droplets after 21 days of adipogenic
induction. Moreover, in parallel experiments SSc serum-treated ADSC not only exhibited a reduced
expression of the adipocytic markers perilipin and adiponectin together with a significant upregulation
of mesenchymal/myofibroblast markers, such as α-SMA+ stress fibers, S100A4 and type I collagen,
but also functionally acquired a myofibroblast-like contractile phenotype. Since adiponectin has
recently been shown to act as an endogenous anti-fibrotic mediator [49], we speculate that the decrease
in adiponectin expression might have a prominent role in the SSc serum-induced acquisition of
myofibroblastic features by ADSC. Of note, the results of the present study are in line with previous
in vitro findings from our group demonstrating that sera from SSc patients may exert a profibrotic effect
on another kind of cells, namely the transdifferentiation of dermal microvascular endothelial cells into
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myofibroblasts [6]. Furthermore, another report demonstrated that exosomes purified from the serum
of SSc patients can effectively induce a profibrotic phenotype in cultured normal dermal fibroblasts [50].
Focusing on adipose tissue cells, both ADSC isolated from the abdominal fat of SSc patients and
ADSC harvested from bleomycin-treated mice were found to display an anti-adipogenic/profibrotic
phenotype, including a reduced capacity for adipogenic differentiation and an increased expression
of the myofibroblast marker α-SMA respect to healthy ADSC [29]. In addition, it is worth noting
that previous studies have clearly shown that a myofibroblastic phenotype is inducible in cultured
undifferentiated ADSC or ADSC-derived preadipocytes by treatment with TGFβ, which is considered
a leading profibrotic orchestrator in SSc pathogenesis through both canonical and non-canonical
signaling pathways [1,14,29]. In this regard, the herein demonstration that changes in the phenotypic
and functional characteristics of normal ADSC upon treatment with SSc serum and recombinant
TGFβ are comparable further supports that the peculiar SSc pathologic environment may direct
the differentiation of ADSC toward a profibrotic fate. Indeed, we verified that TGFβ1 levels were
raised in SSc sera, though we believe that multiple serum factors may likely contribute to induce an
anti-adipogenic and profibrotic phenotype of ADSC. Anyway the role of TGFβ may be dominant in
this context, as also suggested by the recent evidence that this pleiotropic cytokine is even capable
of promoting age-related adipogenic-to-fibrotic switch of dermal fibroblasts [51]. Consistent with
the aforementioned in vitro observations, the notion that adipose tissue-resident stem/progenitor
cells may contribute to the accumulation of fibrogenic myofibroblasts and the development of skin
sclerosis is substantiated by cell fate mapping studies in the most widely used preclinical model of SSc,
namely mice with bleomycin-induced scleroderma, where the majority of pathogenic myofibroblasts
were found to arise from adiponectin-positive progenitors resident in the dermal white adipose
tissue [14,15]. Interestingly, it appears that mature adipocytes may represent an additional source of
profibrotic myofibroblasts [52]. In particular, it has recently been proposed that, through a two-step
process, mature adipocytes de-differentiate into a kind of preadipocytes (referred to as adipose-derived
preadipocytes) that then transdifferentiate into myofibroblasts [52]. Of note, this novel scenario is
fully consistent with the evidence that in bleomycin-induced skin fibrosis the process of myofibroblast
production and fibrosis is secondary to significant reduction of the dermal adipose tissue and, therefore,
will deserve a thorough investigation in SSc.
In a context in which the adipose-derived SVF is receiving growing attention as an innovative
biotherapy for SSc because of its abundance of stem/progenitor cells, of its accessibility and easy
harvesting [42–44], our present results, together with those of previous works [14,15,29], highlight that
an in-depth understanding of the differentiation potential and behavior of ADSC in a diseased milieu
should not be overlooked. Indeed, the composition of adipose-derived SVF is very heterogeneous
as, although ADSC represent its major constituents, it includes also endothelial cells/progenitors,
pericytes, and hematopoietic and immune cells that may provide numerous mechanisms responsible
for its therapeutic effects [46]. Specifically, several data published over the last few years support
the possible clinical efficacy of regional implantation of autologous adipose-derived SVF to treat
hand disability or promote healing of digital ulcers in SSc patients [40–44]. In a recent study
that investigated the cellular and molecular profiles of therapeutic-grade adipose-derived SVF, the
distribution of the various cell subpopulations was not different between patients with SSc (15 with
limited cutaneous SSc and 9 with dcSSc) and healthy donors, and SSc SVF exhibited only slightly
impaired vasculogenic/angiogenic potential either in vitro or in vivo [46]. However, a differential
endothelial and stromal cell molecular signature of the adipose-derived SVF from SSc patients reflecting
endothelial activation, deregulation of angiogenesis and fibrosis was revealed by global and single-cell
RNA-sequencing and analyses of SVF-derived secreted factors [46]. In addition, another study analyzed
the composition of adipose-derived SVF from 6 patients with dcSSc and found a reduced number of cells
with a stem-like phenotype, a high content of proinflammatory cytokines and a shortage of angiogenic
factors [45]. Furthermore, SSc SVF-derived ADSC were shown to retain high multipotency, but failed
to sustain terminally differentiated adipocyte, osteocyte and chondrocyte progenies [45]. At variance
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with the aforementioned findings, other two studies comparing the properties of ADSC isolated
from SSc patients with their healthy counterpart either reported similar proliferation, differentiation
and immunosuppressive potentials [53], or revealed identical differentiation capacity but reduced
proliferation and migration [54]. A very recent report has also shown that explanted SSc ADSC have
profibrotic and anti-adipogenic features, including high levels of the myofibroblast marker α-SMA and
low expression of both anti-fibrotic caveolin-1 and the adipogenic marker FABP4 [29]. Collectively,
such discrepant findings derived from these relatively small studies might be related to differences in
ADSC isolation, culture protocols and proliferative stage in culture, as well as the well-known clinical
heterogeneity of SSc.
5. Conclusions
In summary, our data suggest that the SSc pathologic milieu may favor the differentiation of
normal ADSC into profibrotic myofibroblast-like cells. This evidence may add up to recent data on
ADSC isolated from SSc patients and murine skin fibrosis [29], strengthening the notion that adipose
tissue-resident stem/progenitor cells may be relevant in SSc pathophysiology and might represent new
targets for the prevention and treatment of multiorgan fibrosis. In perspective, further work is warranted
to help in deciphering the specific systemic factors and signaling pathways that in SSc may drive the
differentiation of ADSC into pathogenic myofibroblasts, potentially representing novel therapeutic
targets. Our findings also encourage further investigation into the understanding of how ADSC can
impact upon tissue fibrosis. Indeed, the possibility that ADSC populating the adipose-derived SVF
may behave as a source of profibrotic myofibroblasts should be carefully considered when planning
SVF-based therapeutic approaches in SSc patients. Therefore, only an in-depth cellular and molecular
characterization of SVF and in vitro-expanded ADSC in larger SSc cohorts that include also different
disease subsets might help in identifying and predicting which patients will be more likely to benefit
from an autologous therapeutic approach.
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